Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 6 |
| List of Tables | 5 | 2 |
| List of Figures | 7 | 2 |
| Emerging Market for Clinical Trials - Poland - Introduction | 9 | 1 |
| GBI Research Report Guidance | 9 | 1 |
| Emerging Market for Clinical Trials - Poland - Overview | 10 | 16 |
| The Clinical Research Process- Overview | 10 | 1 |
| Drug Discovery | 11 | 1 |
| Preclinical Study/Development | 11 | 1 |
| Clinical Trials | 11 | 1 |
| The Phases of a Clinical Trial | 12 | 1 |
| Clinical Trial Design and Types | 13 | 1 |
| Types of Design | 13 | 1 |
| Parallel Group Trial Design | 13 | 1 |
| Cross over Trial Design | 14 | 1 |
| Adaptive Clinical Trial Design | 15 | 2 |
| Wyeth s Learn &Confirm Model | 17 | 2 |
| Role of CROs | 19 | 1 |
| Sponsors of Clinical Trials | 20 | 1 |
| The Need for Outsourcing Clinical Trials | 21 | 1 |
| High Risks and Costs Associated With Drug Development | 21 | 1 |
| Escalating Costs of Clinical Trials | 22 | 1 |
| Global Increase in the Number of Clinical Trials Conducted | 23 | 1 |
| Restructuring the R&D | 24 | 1 |
| Increased Screening Rates during R&D | 25 | 1 |
| Expiring Patents Pressurize Pharmaceutical Companies to Reduce Costs | 25 | 1 |
| Emerging Market for Clinical Trials - Poland - Clinical Trial Trends | 26 | 23 |
| Clinical Trials Registered Globally | 26 | 1 |
| Clinical Trials Registered in Eastern European Countries | 27 | 2 |
| Analysis of Clinical Trials Registered in Poland | 29 | 1 |
| Clinical Trials Registered in 1995-2010 | 29 | 2 |
| Analysis of Clinical Trials Registered in 2010 | 31 | 1 |
| Registration of Phase l Clinical Trials | 32 | 1 |
| Registration of Phase ll Clinical Trials | 33 | 1 |
| Registration of Phase lll Clinical Trials | 34 | 1 |
| Registration of Phase lV Clinical Trials | 35 | 1 |
| Clinical Trials Registered by Therapeutic Area | 36 | 1 |
| Comparative Analysis of Industry Sponsored Clinical Trials Registered in US Trials Registry in the Eastern Europe Countries | 37 | 1 |
| Analysis of Clinical Trials Registered by MNCs in Poland | 38 | 2 |
| Sites for Industry Sponsored Clinical Trials Worldwide | 40 | 2 |
| Sites for Industry Sponsored Clinical Trials Registered in Eastern European Countries | 42 | 1 |
| Number of Registered Sites for Industry Sponsored Clinical Trials (Phase II/III) | 42 | 1 |
| Number of Multi-national Sites Registered for Industry Sponsored Trials (Phase II/III) | 43 | 1 |
| Number of Multinational Sites Registered for Industry Sponsored Phase II Trials | 44 | 1 |
| Number of Multi-national Sites Registered for Industry Sponsored Phase III Trials | 45 | 1 |
| Number of Local Sites Registered for Industry Sponsored Trials (Phase II/III) | 46 | 1 |
| Number of Local Sites Registered for Industry Sponsored Phase II Trials | 47 | 1 |
| Number of Local Sites Registered for Industry Sponsored Phase III Trials | 48 | 1 |
| Emerging Market for Clinical Trials - Poland - Market Environment Characterization | 49 | 26 |
| Global CRO Market | 49 | 1 |
| Pipeline Analysis of Five Major Pharmaceutical Companies | 50 | 1 |
| Clinical Trial Market in Poland | 51 | 2 |
| Key Drivers of Clinical Trials Market in Poland | 53 | 1 |
| Population Statistics | 53 | 1 |
| Comparison of Population between Eastern European Countries | 53 | 1 |
| Population Forecast of Poland | 54 | 2 |
| Patient Availability for Major Diseases | 56 | 1 |
| Number of Deaths Occurring by Major Diseases in Poland | 56 | 1 |
| HIV/AIDS | 57 | 1 |
| Diabetes | 58 | 1 |
| Cancer | 59 | 1 |
| Patient Recruitment and Speed of Trials | 60 | 1 |
| Patients per Clinical Trial Worldwide | 60 | 1 |
| Patients per Clinical Trial in Eastern European Countries | 61 | 1 |
| Patients per Clinical Trial in Poland | 62 | 1 |
| Patients per Trial Site in Eastern European Countries | 63 | 1 |
| Patients per Trial Site in Poland | 64 | 1 |
| Patients and Clinical Trial Sites Density | 65 | 1 |
| Patients per Million Population in Eastern European Countries | 65 | 1 |
| Clinical Trial Sites per Million Population in Eastern European Countries | 66 | 1 |
| Qualified and Experienced Talent Pool | 67 | 1 |
| Increase in Number of FDA Regulated Principal Investigators Worldwide | 67 | 1 |
| Increase in the Number of FDA Regulated Principal Investigators in Poland | 68 | 1 |
| Favorable Clinical Infrastructure in Poland Enhances the Clinical Trial Environment | 69 | 1 |
| Health Care Professionals Density Per 10,000 Population | 69 | 2 |
| Hospital Beds Density Per 10,000 Population | 71 | 1 |
| Comparative Analysis of Cost of Clinical Trials amongst Countries Worldwide | 72 | 1 |
| Quality of Clinical Trial Data | 72 | 2 |
| Key Restraints of Clinical Trials Market in Poland | 74 | 1 |
| Long Trial Registration Process | 74 | 1 |
| Other Restraints | 74 | 1 |
| Emerging Market for Clinical Trials - Poland - Regulatory Landscape | 75 | 13 |
| Introduction | 75 | 1 |
| Regulatory Provisions in Poland Related to Clinical Trials | 76 | 1 |
| Major Regulatory Authorities and Trial Registration Process in Poland | 77 | 1 |
| Major Regulatory Authorities in Poland | 77 | 1 |
| Authorizations and Approval Process for Clinical Trials in Poland | 77 | 3 |
| Documents to be Submitted for Conducting a Clinical Trial in Poland | 80 | 1 |
| Documents to be Submitted to the Registration Office for Conducting a Clinical Trial | 80 | 1 |
| Documents to be Submitted to the Bioethics Committee for Conducting a Clinical Trial | 81 | 2 |
| Documents Required With the Investigator and Sponsor of Clinical Trials | 83 | 1 |
| Documents to be Located in the Files of Investigator and Sponsor before the Commencement of Clinical Trials | 83 | 2 |
| Documents to be Located in the Files of Investigator and Sponsor during the Clinical Conduct of Trials | 85 | 1 |
| Documents to be Located in the Files of Investigator and Sponsor after Completion of Clinical Trials | 86 | 1 |
| Possible Regulatory Changes in Clinical Trials | 87 | 1 |
| Emerging Market for Clinical Trials - Poland - CRO Landscape | 88 | 10 |
| CRO Profiles | 88 | 1 |
| Quintiles Poland | 88 | 1 |
| Business Description | 88 | 1 |
| Covance | 89 | 1 |
| Business Desription | 89 | 1 |
| Kendle | 90 | 1 |
| Business Description | 90 | 1 |
| PPD | 91 | 1 |
| Business Description | 91 | 1 |
| Chiltern | 92 | 1 |
| Business Description | 92 | 1 |
| ICON plc. | 93 | 1 |
| Business Description | 93 | 1 |
| PRA International | 94 | 1 |
| Business Description | 94 | 1 |
| PAREXEL | 95 | 1 |
| Business Description | 95 | 1 |
| Lambda Therapeutic Research | 96 | 1 |
| Business Description | 96 | 1 |
| Synexus | 96 | 1 |
| Business Description | 96 | 1 |
| KCR | 96 | 1 |
| Business Description | 96 | 1 |
| Prosen | 96 | 1 |
| Business Description | 96 | 1 |
| Major Deals in the CRO Market | 97 | 1 |
| Emerging Market for Clinical Trials - Poland - Appendix | 98 | 6 |
| Market Definitions | 98 | 1 |
| Abbreviations | 98 | 1 |
| Research Methodology | 99 | 4 |
| Coverage | 99 | 1 |
| Secondary Research | 99 | 1 |
| Primary Research | 99 | 1 |
| Expert Panel Validation | 100 | 1 |
| Section-wise Research Methodology | 100 | 1 |
| Clinical Trials Overview | 100 | 1 |
| Clinical Trial Trends | 100 | 1 |
| Market Environment Characterization | 101 | 1 |
| Regulatory Landscape | 101 | 1 |
| CRO landscape | 102 | 1 |
| Contact Us | 102 | 1 |
| Disclaimer | 102 | 1 |
| Sources | 103 | 1 |